Recommendations on the use of COVID-19 vaccines (2021-09-28)

This evergreen document will be updated as COVID-19 vaccines are authorized and become available for use in Canada, and as evidence on these vaccines and COVID-19 evolves. This table summarizes the latest changes to this current version. Please refer to the Table of updates for a full list of updates to previous versions.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Recommandations sur l’utilisation des vaccins contre la COVID-19 [2021-09-28]
Update Frequency unknown
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2021-10-22 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Recommandations", "utilisation", "vaccins", "contre", "la COVID-19", "2021", "September", "Vaccins", "immunisation", "Comité", "consultatif", "national", "immunisation", "CCNI", "Déclarations", "publications", "Méthodologie", "Épidémiologie", "Résumé", "facteurs", "risque", "liés", "complications", "sévères", "attribuables", "risque", "accru", "exposition", "Vaccins", "Préparations", "utilisation", "approuvée", "Tableau", "Vaccins", "contre", "utilisation", "approuvée", "Efficacité", "potentielle", "efficacité", "réelle", "Immunogénicité", "Administration", "vaccins", "Calendrier", "immunisation", "vaccin", "COVID", "Dépistage", "sérologique", "Conditions", "entreposage", "Administration", "concomitante", "autres", "vaccins", "Innocuité", "manifestations", "cliniques", "inhabituelles", "MCI", "Populations", "spéciales", "Contre-indications", "précautions", "Ingrédients", "associés", "réactions", "allergiques", "autres", "produits", "Interactions", "médicamenteuses", "Produits", "sanguins", "immunoglobulines", "humaines", "moment", "immunisation", "Recommandations", "Résumé", "considérations", "vaccins", "utilisation", "autorisée", "disponible", "Considérations", "matière", "vaccination", "selon", "types", "vaccins", "disponsibles", "approuvée", "Priorités", "matière", "recherche", "Questions", "liées", "surveillance", "Force", "recommandations", "Comirnaty", "Pfizer-BioNTech", "Efficacité", "première", "apparition", "maladie", "symptomatique", "après", "dose", "avant", "la deuxième", "dose", "participants", "16 ans", "plus", "symptomatique", "adolescents", "12 à 15 ans", "Spikevax", "Moderna", "Vaxzevria", "AstraZeneca", "15 jours", "dosage", "ensemble", "efficacité", "de base", "DS/DS", "séronégatif", "apparition", "hospitalisation", "intervalle", "ensemble", "efficacité", "potentielle", "infection", "asymptomatique", "Janssen", "confirmée", "modérée", "sévère", "critique", "se manifestant", "14 jours", "28 jours", "après la vaccination", "ensemble", "conforme", "protocole", "Séquençage", "génétique", "variant", "préoccupant", "septembre", "décembre", "2020", "pays", "comptant plus", "de 100 cas", "PCR", "centrale", "sites", "locaux", "confirmés", "manière", "centralisée", "centralisée", "sérologique", "ensemble", "protocole", "évènements", "indésirables", "locaux", "sollicités", "administration", "vaccins", "essais cliniques"], "en": ["Vaccines", "immunization", "National", "Advisory", "Committee", "Immunization", "NACI", "Statements", "publications", "Recommendations", "use", "COVID-19", "vaccines", "Methods", "Epidemiology", "Summary", "risk", "factors", "severe", "outcomes", "COVID", "increased", "exposure", "Preparations", "authorized", "Canada", "efficacy", "effectiveness", "Immunogenicity", "administration", "schedule", "serological", "testing", "Storage", "requirements", "Concomitant", "administration", "other", "safety", "adverse", "events", "following", "AEFI", "Special", "populations", "Contraindications", "precautions", "Ingredients", "associated", "allergic", "reactions", "products", "Drug", "interactions", "Blood", "products", "human", "immunoglobulin", "timing", "immunization", "Recommendations", "Vaccination", "considerations", "types", "Research", "priorities", "Surveillance", "issues", "Strength", "NACI", "Clinical", "trial", "evidence", "Pfizer-BioNTech", "Comirnaty", "against", "first occurrence", "symptomatic", "disease", "after dose 1", "before dose 2", "participants", "16 years", "age and older", "adolescents", "12 to 15 years", "Moderna", "Spikevax", "AstraZeneca", "Vaxzevria", "Estimates", "vaccine", "efficacy", "against", "first", "occurrence", "confirmed", "15 days", "dosing", "interval", "SD/SD", "seronegative", "baseline", "set", "hospitalization", "asymptomatic", "infection", "Janssen", "14 days", "28 daysm post-vaccination", "per-protocolm", "Genetic", "sequencing", "results", "VOC", "September-December", "2020", "symptomatic", "by country", "for countries", "greater", "100 moderate", "to severe", "critical cases", "centrally", "in-country", "PCR-confirmed", "cases", "moderate"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source